View Cart ()
Your cart is empty
-
New: Sponsored, no-charge genetic testing and counseling for individuals diagnosed with pancreatic cancer. Learn more.
-
New: Reata and Invitae are offering a sponsored, no-charge genetic testing program for chronic kidney disease. Learn more.
-
SMA Identified: Now more testing options to help confirm a clinical diagnosis or assess the carrier status of SMA. Learn more.
Follow our progress.
Milestones in our journey to reinvent genetic testing.
Back to full list
Press Releases
Invitae Corporation files registration statement for proposed initial public offering
January 09, 2015
SAN FRANCISCO —January 9, 2015—Invitae Corporation announced today that it has filed a registration statement on Form S‐1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Invitae intends to apply to list its common stock on The New York Stock Exchange under the symbol “NVTA.”
J.P. Morgan ...
